Zobrazeno 1 - 10
of 87
pro vyhledávání: '"B Leticia Rodriguez"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d3a718cfea8d45759089e96d15759b9d
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3599253760644e7b9e7507a2986a8280
Autor:
Jing Wang, Jianjun Zhang, Ignacio Wistuba, Lixia Diao, Don Gibbons, Stephanie Schmidt, Haoyi Wu, Jessica M Konen, B Leticia Rodriguez, Jared Fradette, Laura Gibson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7e400a6ece96446abdebcaf1a9c03ace
Autor:
Jessica M. Konen, B. Leticia Rodriguez, Haoyi Wu, Jared J. Fradette, Laura Gibson, Lixia Diao, Jing Wang, Stephanie Schmidt, Ignacio I. Wistuba, Jianjun Zhang, Don L. Gibbons
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 17 (2023)
Non–small cell lung cancers that harbor concurrent KRAS and TP53 (KP) mutations are immunologically warm tumors with partial responsiveness to anti–PD-(L)1 blockade; however, most patients observe little or no durable clinical benefit. To identif
Externí odkaz:
https://doaj.org/article/c91ebec70cb74fa7b67c8100444ae89e
Autor:
B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionDespite significant clinical advancement with the use of immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) there are still a major subset of patients that develop adaptive/acquired resistance. Understanding resistance
Externí odkaz:
https://doaj.org/article/b7f1eb8f62594da3a8e2703ca0fd91c7
Autor:
David H. Peng, B. Leticia Rodriguez, Lixia Diao, Pierre-Olivier Gaudreau, Aparna Padhye, Jessica M. Konen, Joshua K. Ochieng, Caleb A. Class, Jared J. Fradette, Laura Gibson, Limo Chen, Jing Wang, Lauren A. Byers, Don. L. Gibbons
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Recent clinical trials combining MEK inhibitors with anti-PD-L1 in solid tumours show moderate responses. Here, the authors demonstrate that the combination of MEK inhibition and PD-L1 blockade in KRAS mutant lung cancer models leads to a transient t
Externí odkaz:
https://doaj.org/article/c550e9da14dd40faac0c52202ab9def2
Autor:
Hou-Fu Guo, Neus Bota-Rabassedas, Masahiko Terajima, B. Leticia Rodriguez, Don L. Gibbons, Yulong Chen, Priyam Banerjee, Chi-Lin Tsai, Xiaochao Tan, Xin Liu, Jiang Yu, Michal Tokmina-Roszyk, Roma Stawikowska, Gregg B. Fields, Mitchell D. Miller, Xiaoyan Wang, Juhoon Lee, Kevin N. Dalby, Chad J. Creighton, George N. Phillips, John A. Tainer, Mitsuo Yamauchi, Jonathan M. Kurie
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-10 (2021)
Guo et al. determine the molecular basis of collagen lysyl hydroxylase 2 (LH2) substrate specificity. They further show that LH2 also functions as a collagen glucosyltransferase to promote lung cancer progression.
Externí odkaz:
https://doaj.org/article/33c609a5058f4848b50950a0e6133563
Autor:
Aparna Padhye, Jessica M. Konen, B. Leticia Rodriguez, Jared J. Fradette, Joshua K. Ochieng, Lixia Diao, Jing Wang, Wei Lu, Luisa S. Solis, Harsh Batra, Maria G. Raso, Michael D. Peoples, Rosalba Minelli, Alessandro Carugo, Christopher A. Bristow, Don L. Gibbons
Publikováno v:
JCI Insight, Vol 6, Iss 17 (2021)
Lack of sustained response to therapeutic agents in patients with KRAS-mutant lung cancer poses a major challenge and arises partly due to intratumor heterogeneity that defines phenotypically distinct tumor subpopulations. To attain better therapeuti
Externí odkaz:
https://doaj.org/article/68b2c3b3409d42f9a4a84381305fc816
Autor:
Mabel Perez-Oquendo, Roxsan Manshouri, Yanhua Tian, Jared J. Fradette, B. Leticia Rodriguez, Samrat T. Kundu, Don L. Gibbons
Publikováno v:
Molecular Cancer Research. :OF1-OF16
Epithelial-to-mesenchymal transition results in loss of specialized epithelial cell contacts and acquisition of mesenchymal invasive capacity. The transcription repressor zinc finger E-box-binding homeobox 1 (ZEB1) binds to E-boxes of gene promoter r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef9fd47ed40eeb3e8b97b12af14c07ab
https://doi.org/10.1158/1541-7786.mcr-22-0503
https://doi.org/10.1158/1541-7786.mcr-22-0503
Autor:
Neus Bota-Rabassedas, Priyam Banerjee, Yichi Niu, Wenjian Cao, Jiayi Luo, Yuanxin Xi, Xiaochao Tan, Kuanwei Sheng, Young-Ho Ahn, Sieun Lee, Edwin Roger Parra, Jaime Rodriguez-Canales, Jacob Albritton, Michael Weiger, Xin Liu, Hou-Fu Guo, Jiang Yu, B. Leticia Rodriguez, Joshua J.A. Firestone, Barbara Mino, Chad J. Creighton, Luisa M. Solis, Pamela Villalobos, Maria Gabriela Raso, Daniel W. Sazer, Don L. Gibbons, William K. Russell, Gregory D. Longmore, Ignacio I. Wistuba, Jing Wang, Harold A. Chapman, Jordan S. Miller, Chenghang Zong, Jonathan M. Kurie
Publikováno v:
Cell Reports, Vol 35, Iss 3, Pp 109009- (2021)
Summary: Cancer cells function as primary architects of the tumor microenvironment. However, the molecular features of cancer cells that govern stromal cell phenotypes remain unclear. Here, we show that cancer-associated fibroblast (CAF) heterogeneit
Externí odkaz:
https://doaj.org/article/2c651979e55c43638647e4def6c85ef2